Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
Dogwood Therapeutics, Inc. (Nasdaq: DWTX), a biopharmaceutical firm in its development stage, centered on bringing forth pioneering class, non-opioid treatments such as the Nav 1.7 inhibitor for chronic and acute pain, announced that the first patient set to participate in its Phase 2b clinical trial, labeled HALT-CINP (Halneuron® Treatment of Chemotherapy Induced Neuropathic Pain), is anticipated to get their first dosage in the first quarter of 2025.
Halneuron® is a trailblazing, Nav 1.7 specific voltage gated sodium channel inhibitor developed as a substitute for opioid pain treatment. In a prior Phase 2 clinical trial, patients treated with Halneuron® showed a statistically significant decrease in cancer-related pain, with an acceptable safety standard. Over 700 patients have been involved in a series of Phase 1 and Phase 2 studies of Halneuron®, showing no signs of addiction.
“Chemotherapy is beneficial but often presents challenging side effects for patients, such as fever, tiredness, infection, hair loss, neuropathy, and pain,” says Dr. R. Michael Gendreau, the Chief Medical Officer of Dogwood Therapeutics, Inc. “Studies imply that one out of three patients treated with certain chemotherapeutics including taxanes and platinum drugs develop chronic painful neuropathy. There are currently no approved treatments for chronic neuropathy, and off-label treatment with available analgesics is generally not effective. Roughly one in every three cancer patients is treated with opioids according to market data.”
The lead Halneuron® target indication in CINP represents a significant area of high unmet medical need and a market valued at approximately $1.5B,” stated Greg Duncan, Chairman and CEO of Dogwood Therapeutics, Inc. “Our executive team at Dogwood has a history of developing and/or bringing blockbuster medicines to the market, including pain therapeutics Celebrex, Lyrica and Savella.”
